Casey Graham, Lindor Noralane M, Papadopoulos Nickolas, Thibodeau Stephen N, Moskow John, Steelman Scott, Buzin Carolyn H, Sommer Steve S, Collins Christine E, Butz Malinda, Aronson Melyssa, Gallinger Steven, Barker Melissa A, Young Joanne P, Jass Jeremy R, Hopper John L, Diep Anh, Bapat Bharati, Salem Michael, Seminara Daniela, Haile Robert
Department of Cancer Biology, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio 44195, USA.
JAMA. 2005 Feb 16;293(7):799-809. doi: 10.1001/jama.293.7.799.
The accurate identification and interpretation of germline mutations in mismatch repair genes in colorectal cancer cases is critical for clinical management. Current data suggest that mismatch repair mutations are highly heterogeneous and that many mutations are not detected when conventional DNA sequencing alone is used.
To evaluate the potential of conversion analysis compared with DNA sequencing alone to detect heterogeneous germline mutations in MLH1, MSH2, and MSH6 in colorectal cancer patients.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter study with patients who participate in the Colon Cancer Family Registry. Mutation analyses were performed in participant samples determined to have a high probability of carrying mismatch repair germline mutations. Samples from a total of 64 hereditary nonpolyposis colorectal cancer cases, 8 hereditary nonpolyposis colorectal cancer-like cases, and 17 cases diagnosed prior to age 50 years were analyzed from June 2002 to June 2003.
Classification of family members as carriers or noncarriers of germline mutations in MLH1, MSH2, or MSH6; mutation data from conversion analysis compared with genomic DNA sequencing.
Genomic DNA sequencing identified 28 likely deleterious exon mutations, 4 in-frame deletion mutations, 16 missense changes, and 22 putative splice site mutations. Conversion analysis identified all mutations detected by genomic DNA sequencing--plus an additional exon mutation, 12 large genomic deletions, and 1 exon duplication mutation--yielding an increase of 33% (14/42) in diagnostic yield of deleterious mutations. Conversion analysis also showed that 4 of 16 missense changes resulted in exon skipping in transcripts and that 17 of 22 putative splice site mutations affected splicing or mRNA transcript stability. Conversion analysis provided an increase of 56% (35/63) in the diagnostic yield of genetic testing compared with genomic DNA sequencing alone.
The data confirm the heterogeneity of mismatch repair mutations and reveal that many mutations in colorectal cancer cases would be missed using conventional genomic DNA sequencing alone. Conversion analysis substantially increases the diagnostic yield of genetic testing for mismatch repair mutations in patients diagnosed as having colorectal cancer.
准确识别和解读结直肠癌病例中错配修复基因的种系突变对于临床管理至关重要。目前的数据表明,错配修复突变具有高度异质性,仅使用传统DNA测序时,许多突变无法被检测到。
评估与单独DNA测序相比,转化分析检测结直肠癌患者中MLH1、MSH2和MSH6基因异质性种系突变的潜力。
设计、地点和参与者:对参与结肠癌家族登记处的患者进行多中心研究。对确定携带错配修复种系突变可能性高的参与者样本进行突变分析。2002年6月至2003年6月,共分析了64例遗传性非息肉病性结直肠癌病例、8例遗传性非息肉病性结直肠癌样病例和17例50岁前诊断的病例的样本。
将家庭成员分类为MLH1、MSH2或MSH6基因种系突变的携带者或非携带者;转化分析与基因组DNA测序的突变数据比较。
基因组DNA测序鉴定出28个可能有害的外显子突变、4个框内缺失突变、16个错义变化和22个推定的剪接位点突变。转化分析鉴定出基因组DNA测序检测到的所有突变,另外还有1个外显子突变、12个大的基因组缺失和1个外显子重复突变,有害突变的诊断率提高了33%(14/42)。转化分析还表明,16个错义变化中有4个导致转录本中外显子跳跃,22个推定的剪接位点突变中有17个影响剪接或mRNA转录本稳定性。与单独的基因组DNA测序相比,转化分析使基因检测的诊断率提高了56%(35/63)。
数据证实了错配修复突变的异质性,并表明仅使用传统基因组DNA测序会遗漏许多结直肠癌病例中的突变。转化分析显著提高了诊断为结直肠癌患者错配修复突变基因检测的诊断率。